Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Michael T. Constantino is Director at Humacyte. OQRO lists 4 transactions filed with the SEC under this name, the latest on Jun 12, 2026, each linked to the official Form 4.
Director
Disclosures on record
4
Companies involved
1
3 buys, median −25.9 pts vs S&P 500, beat it 1 of 3 times.
Average −0.8 pts vs S&P 500. Each buy is one disclosure of open-market purchases in one company on one filing date, filed Dec 4, 2024 to May 20, 2026, measured from the first close after the filing. Past results, not a forecast.
3 purchases disclosed; 33% of the 3 measured at 90 days finished ahead of the index. $1,000 placed after each of the 1 purchases disclosed since 2025-11-14 would be worth $547 today ($1K put in); the same in the S&P 500 (SPY): $1K.
Not ranked: fewer than 10 purchases measured at 90 days. The middle of the 82 ranked insiders is −5.5 pts (median, against the S&P 500).
HumacyteHUMA
4 disclosures · Dec 2024 – Jun 2026 · 3 bought
Jun 11, 202680Kdisclosed Jun 12
DetailsOfficial recordMay 18, 2026Bought~$9.8Kdisclosed May 20
DetailsOfficial recordEqual weight counts every purchase once; by size counts it for its disclosed dollars. Both are measured from the first close after it was reported. Past results describe the past, not a forecast. How this is measured · Leaderboard
Apr 7, 2025Bought~$20Kdisclosed Apr 8
DetailsOfficial recordDec 4, 2024Bought~$20K
DetailsOfficial recordAs of the latest filing on , Michael T. Constantino reported holding 43,950 shares of Humacyte (HUMA), worth about $25K at the last close of $1 (Nov 13, 2026). In the last 12 months, Michael T. Constantino bought $9.8K in 1 open-market purchase.
| Company | Shares reported | How held | Last close | Value at last close | Reported |
|---|---|---|---|---|---|
| Humacyte HUMA | 43,950 | 44K direct | $1 | $25K | May 18, 2026 |
Is this Michael T. Constantino’s net worth? No. A Form 4 reports the shares an insider owns in one company after each transaction, directly or through trusts and entities. It says nothing about cash, other investments, property or debt, options not yet exercised are not counted here, and a holding reported some time ago may have changed without a new filing. The value is shares times the last stored close, not a price anyone received. Sources: the filings listed below, each linked to EDGAR. Compare with the biggest insider stakes.
On the latest SEC Form 4, dated May 18, 2026, Michael T. Constantino reported holding 43,950 shares of Humacyte (HUMA). At the last close of $1 on Nov 13, 2026, that is about $25K. This is the stake disclosed in filings, not a net worth.
In SEC filings of the last 12 months, Michael T. Constantino reported 1 open-market purchase worth $9.8K, and no open-market sale. Shares withheld for taxes, gifts and option exercises are not counted in these totals.
Michael T. Constantino bought shares on the open market in 2021, 2022, 2023, 2024, 2025 and 2026.
In SEC filings since 2021: the latest open-market purchase is from 2026; no open-market sale is on record.
Humacyte (HUMA), from 2021 to 2026: 8 purchases and 0 sales.
Michael T. Constantino bought shares on the open market in 2021, 2022, 2023, 2024, 2025 and 2026.
Michael T. Constantino reported 8 open-market purchases and 0 sales since 2021; purchases in 6 different years, most recently 2026.
| Year | Bought | Sold |
|---|---|---|
| 2026 | $9.8K1×1 trade | — |
| 2025 | $20K1×1 trade | — |
| 2024 | $40K2×2 trades | — |
| 2023 | $20K1×1 trade | — |
| 2022 | $9.7K1×1 trade | — |
| 2021 | $27K2×2 trades | — |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Michael T. Constantino reported 8 open-market purchases and 0 sales here, 2021 to 2026.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.